

Research Article

Characterisation of Antibiotic Genes of *Acinetobacter baumannii* Isolated from Patients in Baghdad Hospitals

Omer Faris Hasan¹, Balqees Yahya Najm^{2*}, Hala Mohmmmed Majeed³, Sarab Hussein Khallel⁴

^{1,2,3,4}Basic Science Department, Medicine College, Ibsnina of Medical and Pharmaceutical Sciences University, Iraq.

DOI: <https://doi.org/10.24321/0019.5138.202352>

I N F O

Corresponding Author:

Balqees Yahya Najm, Basic Science Department, Medicine College, Ibsnina of Medical and Pharmaceutical Sciences University, Iraq.

E-mail Id:

balqees.yahya@ibnsina.edu.iq

Orcid Id:

<https://orcid.org/0000-0001-6984-2255>

How to cite this article:

Hasan O F, Najm B Y, Majeed H M, Khallel S H. Characterisation of Antibiotic Genes of *Acinetobacter baumannii* Isolated from Patients in Baghdad Hospitals. J Commun Dis. 2023;55(4):38-45.

Date of Submission: 2023-9-24

Date of Acceptance: 2023-10-23

A B S T R A C T

Introduction: The gram-negative bacterium known as *Acinetobacter baumannii* is frequently found in soil and water, as well as in samples taken from animals and humans. This study isolated and identified 50 urine samples from four Baghdad educational hospitals. Method: Biochemical testing, selective synthetic media (CHROMagar), and polymerase chain reaction identified all bacterial samples. Only 20 isolates were identified as *A. baumannii* using a primer targeting the blaOxa-51 gene. Antibiotic susceptibility was tested using disc diffusion with eight antibiotics.

Results and Conclusion: The susceptibility testing of *A. baumannii* to antibiotics revealed that this bacterium had a higher resistance towards cefotaxime (8, 40%), followed by imipenem (6, 30%), gentamycin (5, 15%), and trimethoprim (2, 10%). The resistance was the same for both tetracycline and tobramycin (3, 15%). In contrast, the antibiotics ampicillin-sulbactam and doxycycline encountered a lower level of resistance, specifically 1% and 5% respectively. Analysis of 20 DNA samples of *A. baumannii* revealed the presence of *OmpA* and *CsuE* genes, with a gene size of 168 bp and 162 bp, respectively. The percentage of these genes in the samples was found to be 60%.

Keywords: *Acinetobacter baumannii*, Antibiotics, Resistance, Genes, AMEs

Introduction

The gram-negative bacterium known as *Acinetobacter baumannii* is frequently found in soil and water, as well as in samples taken from animals and humans.^{1,2} The development of endocarditis, infections of the skin and soft tissues, meningitis, urinary tract infections (UTIs), and pneumonia are all significantly influenced by these microorganisms.^{3,4} The fact that these bacteria are

opportunistic microorganisms with innate characteristics that enhance their resistance to a wide variety of medicines is directly responsible for the quick emergence of strains that are resistant to many medications and even extremely resistant to certain pharmaceuticals.⁵ *Acinetobacter* spp. are gram-negative bacteria that are obligate aerobes, non-motile, coccobacilli, non-fermenting, and non-fastidious. They are often observed in diploid formations or chains of different lengths. Additionally, they have

catalase-positive characteristics and do not show oxidase activity.⁶ *Acinetobacter* spp. is a type of bacteria that is commonly found in hospitals and can cause infections such as pneumonia, bloodstream infections associated with catheters, and various clinical illnesses, especially wound infections. It is the most common species responsible for infections and has a patient mortality rate of up to 60%.⁷ Biofilms are microbial aggregations that are created by the microbes themselves and can be found on biotic or abiotic surfaces. They contain exopolysaccharide matrices.⁸ Furthermore, *A. baumannii* is capable of producing biofilms on a wide range of surfaces, including biotic surfaces such as host epithelial cells as well as abiotic surfaces such as stainless steel and polypropylene.⁹ Through the establishment of biofilms, numerous drug resistance mechanisms, such as drug exclusion, permeability defeat, and enzymatic degradation processes, are improved.¹⁰ Evidence indicates that the *A. baumannii* genome harbours a diverse array of virulence factors that are linked to bacterial cell adhesion and have a profound impact on the production of biofilms.¹¹ Colquhoun and Rather have reported that *OmpA* and *CsuE* proteins in *A. baumannii* exhibit the highest degree of conservation, with a presence rate ranging from 81% to 100%.¹² *Acinetobacter* is quite common in hospitals because it can live on dry and moist surfaces.¹ It can cause pneumonia, endocarditis, meningitis, skin and wound infections, peritonitis in peritoneal dialysis patients, urinary tract infections, and bloodstream infections. These diseases are typically associated with endotracheal tubes or tracheostomies.^{2,3} *Acinetobacter*'s antibiotic susceptibility pattern might vary greatly regionally and over time between several hospital departments. In order to select the most suitable therapy, it is essential to regularly check these pathogens because of the variations in the *Acinetobacter* resistogram.^{4,5} It is crucial to identify the common susceptibility profiles due to the diverse multidrug resistance patterns demonstrated by clinical isolates of *Acinetobacter*. Isolating *Acinetobacter* from urine samples was the primary goal of this investigation, which aimed to identify them using a simpler method. The susceptibility of these isolates to different antibiotics was then evaluated.

Material and Method

Bacterial Isolates

During a three-month period from February to April 2023, a total of 50 urine samples were collected from patients at four distinct hospitals in Baghdad, namely Al-Karama, Al-Yarmouk, Al-Kathmyaa, and Al-Mohammadia. Following cultivation on MacConkey's agar (HiMedia, India) and overnight incubation at 37 °C, isolates were obtained from clinical samples. The non-lactose fermenting bacteria,

which were either colourless or slightly brownish, were subsequently transferred to new cultures and cultivated for consecutive overnight periods. The identification was conducted based on morphological and biochemical analyses.^{13,14} The putative bacterial isolates, characterised by gram-negative coccobacillary or diplobacillary cells and negative oxidase results, underwent additional identification using conventional biochemical testing.

Extraction of Genomic DNA

Genomic DNA was isolated from the bacterial growth using the ABIopure Extraction process to serve as a template for PCR amplification. The amplification reaction mixture (25 µl) contained 12.5 µl of GoTaq® Green Master Mix 2X (Promega, USA) and 2.5 µl (10 M) of forward (GCCATAACCAACACGCTTCA) and reverse (GGCAACCCACAGAAGTAT) primers for each gene (Kapa, USA). A DNA thermal cycler, GeneAmp 9700 Thermal Cycler made by the Singaporean firm Applied Biosystem, was used to amplify the 16S ribosomal RNA. Denaturation was first performed at 95 °C for 3 minutes. Then, there were 30 cycles of denaturation at 95 °C for 1 minute, annealing at 55 °C for 1 minute, extension at 72 °C for 1 minute, and finally, an extension step at 72 °C for 5 minutes. The PCR amplicons that were created were analysed using electrophoresis and a gel documentation system called BioDocAnalyze Live, manufactured by Biometra Biomedizinische Analytik GmbH in Germany. The ABIopure extraction procedure was employed to extract genomic DNA from the bacterial growth for subsequent use as a template in PCR amplification.

Antibiotic Susceptibility Test

The disc diffusion method on Muller Hinton agar (Mast, UK) was employed to determine the resistance of bacterial isolates to various antibiotics, following the guidelines set by CLSI in 2020.¹⁵ The antibiotics used in the study were ampicillin-sulbactam (10 µg), cefotaxime (30 µg), imipenem (10 µg), gentamycin (10 µg), tobramycin (10 µg), tetracycline (30 µg), doxycycline (30 µg), and trimethoprim (2 µg). The bacterial isolates were introduced into the culture medium using the streaking technique and were thereafter placed in an incubator at a temperature of 37 °C for a duration of 24 hours. The samples were then examined and analysed.

Detection of Genes Responsible for Biofilm Formation

The detection of *OmpA* and *CsuE* genes was conducted using a designated set of primers as indicated in Table 1. The detection was performed by amplifying the *OmpA* and *CsuE* genes in the DNA template isolated from *A. baumannii* using a reaction mixture with a volume of 25 µl for each gene. The PCR amplification products were subjected to electrophoresis on a 2.5% agarose gel.

Table 1. Sequence of Specific Primers

Names of Genes	Sequence of Genes 3 – 5	Product Size (bp)
OmpA	TGCTCCACAACCACAAGAGT GGCAACCACCACAGAAGTAT	162
CsuE	CATCTTCTATTTCCGGTCCC CGGTCTGAGCATTGGTAA	168

Results and Discussion


According to the data, only 20 out of the 50 samples were identified as *A. baumannii* isolates. Table 2 displays the distribution of the observed *Acinetobacter baumannii* in the four hospitals located in Baghdad's different regions.

Table 2. Percentage of *A. baumannii* Bacteria in Different Educational Hospitals


Regions	n (%)
Al-Karama	5 (25)
Al-Yarmouk	10 (50)

Al-Kathmyaa	3 (15)
Al-Mohammadia	2 (10)

Based on the CHROMagar results, 20 out of the 50 bacterial isolates were determined to be *A. baumannii*. The microscopy and biochemical examinations identified the presence of gram-negative cocci exhibiting catalase-positive properties and yielding negative results in oxidase and nitrate reduction assays. In addition, the isolates showed negative results for the Simmons citrate test and positive results for the indole test. The results of biochemical and morphological research are consistent with the findings of Falah and his colleagues who successfully identified *A. baumannii* from burn wound swabs taken from patients at a prominent burns hospital in Tehran.¹⁶ Moreover, our results are also in agreement with those of a study in which the existence of the pathogen (44.48%) was accurately detected in samples of sputum, pus, blood, and urine.¹⁷ In order to confirm the identity of these 20 isolates as *A. baumannii*, a molecular identification method was carried out. The process entailed amplifying a particular gene consisting of 187 base pairs. The results unveiled a clearly distinguishable band, as illustrated in Figure 1.



(a)



(b)

Figure 1(a and b). Findings from 20 Bacterial Samples Aliquoted on 1.5% Agarose Gel Electrophoresis for BlaOXA Gene Amplification Traced using a 100 bp ladder marker and Stained with Eth. Br. M. Lanes 1-B Resemble PCR Products

Table 1 shows the primers used for the PCR amplification of the blaOxa-51 gene. They were applied to 60 DNA samples obtained from different bacterial isolates. All isolates of *A. baumannii* were found to be positive for the blaOxa-51 gene and showed a clearly visible band with a molecular size of 178 bp on a 2.5% agarose gel, using an electric field strength of 5 volts/cm² for a duration of 90 minutes. Figure 1 depicts the results of gel electrophoresis. The blaOXA-51-like gene was detected in all isolates examined in the present study. This gene displays a broad distribution and is an inherent trait of the *A. baumannii* species.¹² Previous studies have shown that the blaOxa-51 gene has not been identified in any other *Acinetobacter* species, and is only present in every clinical isolate of *A. baumannii*.¹⁵ The results of our research are consistent with a study that employed PCR to validate the existence of the blaOXA-51 gene, which acts as an indicator for recognising *A. baumannii*. The investigation found that out of the total isolates, 80 accounting for 97.56%, had the target gene.¹⁶ The *A. baumannii* isolates demonstrated resistance to ampicillin-sulbactam, cefotaxime, imipenem, gentamycin, tobramycin, tetracycline, doxycycline, and trimethoprim.

The results of susceptibility of *A. baumannii* showed that these bacteria have a higher resistance to cefotaxime (8, 40%), followed by their resistance to imipenem (6, 30%), gentamycin (5, 15%), and trimethoprim (2, 10%). The resistance percentage was the same for tetracycline and tobramycin (3, 15%). On the other hand, lower resistance was observed to antibiotics ampicillin-sulbactam and doxycycline (1, 5%). The highest resistance was recorded to cefotaxime. This observation aligns with previous reports that observed a heightened resistance of the isolates to this antibiotic.^{12,18} In addition, another study documented a remarkably high level of resistance to cefotaxime, reaching 92%.¹⁹ The current investigation demonstrated a 30% resistance to imipenem. This finding is consistent with the research conducted by Yang and his colleagues, which revealed a 28% prevalence of antibiotic resistance.²⁰ However, it contradicts the findings of the study conducted by Anane et al., in which the resistance to antibiotics reached 83%.²¹ The prevalence of gentamycin resistance in the current investigation was 15%. However, the resistance to gentamycin was shown to be 86% in another investigation.²² The prevalence of *A. baumannii* resistance to tetracycline and tobramycin was below 15%, consistent with the findings reported by El-Badawy et al.,²³ who observed that *A. baumannii* demonstrates resistance to many antibiotics, including tobramycin (59%). Conversely, the occurrence of tetracycline resistance varied in different studies, with one reporting a rate of 62% and another showing an increase to 93%.²⁴ The prevalence of

resistance to this antibiotic has shown a notable decrease, declining from 90.2% in 2010 to 69.14% in 2015, as reported by Dafopoulou et al.²⁵ On the contrary, Abdallah et al.²⁶ unequivocally demonstrated that the resistance rate for this drug was 100%. However, Maraki et al. conducted more investigations and discovered a resistance rate of 63.57%, which can be considered relatively high.²⁷

Due to lack of availability, clinicians had to depend on older antibiotics such as trimethoprim-sulphamethoxazole. Furthermore, the research conducted by certain scientists demonstrated that ampicillin-sulbactam resistance was quite high (77%), while another study showed a resistance of 46%.²⁸ Articles by Lukovic et al. and Safari et al., however, showed that the percentages of ampicillin-sulbactam resistance were 31% and 59.1%, respectively.^{29,30} It was found that the percentage of tetracycline resistance was 62%, which was similar to the percentage found by another researcher (60%).²⁴ Contrary to a study conducted by Abd El-Baky et al. that showed a resistance of 93%, this study did not indicate a very high level of resistance to tetracycline.³¹ With a sensitivity rate of 28%, all isolates exhibited moderate resistance to ceftriaxone (48%). Contrary to what Abbas-Al-Khafaji and Aubais-aljelehwany reported, our results showed that a small percentage of bacterial isolates were ceftriaxone-resistant.³²

A study by Monfared et al. showed that the resistance to doxycycline was 96%.³³ The percentage mentioned here varies from the resistance rate observed in the present investigation, which documented a 46% resistance to the doxycycline drug. Nevertheless, the prevalence of doxycycline resistance reached 57% in another study.³⁴ Conversely, As and Priyadarshini conducted a study which revealed a low resistance (20%) to doxycycline.³⁵ During this study, the highest resistance was recorded to cefotaxime (84%). This result is consistent with that of Musyoki et al.¹⁸ where they recorded a resistance rate of 87%.

The presence of β -lactamases, an enzyme that renders the beta-lactam ring inactive, is another element that contributes to the development of resistance to some antibiotics in *A. baumannii*. Aminoglycosides-modifying enzyme is an example of such an enzyme.³⁶ Three mechanisms of aminoglycoside resistance in *A. baumannii* have been identified: (1) the presence of aminoglycoside-modifying enzymes (AMEs) that lower the antibiotics' affinity for their targets; (2) the randomisation of target sites by 16S rRNA methyl transferases; and (3) the restriction of aminoglycoside uptake due to increased efflux pump activity or loss of permeability.³⁷ The two main processes that have been associated with tetracycline resistance are enzymatic inactivation and ATP-dependent efflux

pumps. One of the biggest public health problems globally, particularly in poor nations, is the frequency of *A. baumannii* infection in various areas of hospitals. Nosocomial infections are caused by *A. baumannii*, a highly significant bacteria that is difficult to control because of its persistence in the hospital environment and resistance to many medications. The number of fatal infections in hospitals has been rising, and some scientists attribute this to infections caused by *A. baumannii*, particularly strains that are resistant to multiple drugs. Isolation of *A. baumannii* from a patient can suggest bacterial colonisation rather than infection, which further complicates efforts to determine the actual frequency of this microbe. Colonisation of patients by *Acinetobacter* species that are resistant to multiple antibiotics has been documented by numerous researchers.

Detection of the Prevalence of OmpA and CsuE Genes by PCR

Using a typical PCR approach and particular primers as specified in Table 1, 20 DNA samples taken from *A. baumannii* were molecularly detected for *OmpA* and *CsuE* genes. The samples were then subjected to gel electrophoresis using agarose gel (2.5% concentration), at 5 volts/cm² for 90 minutes. Figures 2 and 3 indicate the 168- and 162-base pair sizes of the *CsuE* and *OmpA* genes, respectively, in *A. baumannii*, and the results demonstrated that these genes comprised 60% of the total. According to the findings, biofilm generation ability was higher in *A. baumannii* isolates that carried the *CsuE* and *OmpA* genes. Both genes are required for biofilm development.




Figure 2. Results of the Amplification of CsuE Gene of Bacterial Samples Fractionated on 1.5% Agarose Gel Electrophoresis Stained with Eth. Br. M: 100 bp ladder marker. Lanes I-B Resemble PCR products




Figure 3. Results of the Amplification of OmpA Gene of Bacterial Samples Fractionated on 1.5% Agarose Gel Electrophoresis Stained with Eth. Br. M: 100 bp ladder marker. Lanes I-B resemble PCR products

All biofilm producers, including some weak and moderate producers, had the *CsuE* and *OmpA* genes, according to our findings. In addition to these genes, 88% of isolates lacked the ability to form biofilms. This is likely due to a combination of factors, including genes related to biofilms and other physiological processes, as well as nutritional and environmental factors.³⁸ These results agreed with the work of Monfared et al. and Khoshnood et al.^{33,39} which showed a high prevalence of biofilm-related genes *OmpA* and *CsuE*. Also, the *CsuE* gene was present in all isolates in a study,⁴⁰ but other studies showed the percentages of *CsuE* and *OmpA* to be 68% and 81%, respectively.¹¹ Despite the fact that there are numerous alternatives to antibiotics that function as antimicrobials against pathogenic germs, the changes in the above results can be due to the increased application of other drugs against pathogens, which is driven by the increased resistance of bacteria to antibiotics. These variations might have arisen as a result of seasonal, geographical, and unique solvent variations experienced.⁴⁰⁻⁴⁵ An approach that involves detecting harmful microorganisms using Polymerase Chain Reaction (PCR) is used in several medical disciplines to determine the clinical aetiology associated with infectious diseases⁴²⁻⁴⁵ and other harmful genetic disorders; it is regarded as an essential method in medicine.⁴⁶⁻⁵⁷

Conclusion

A. baumannii is responsible for various nosocomial infections. In this study, 20 out of 50 samples were identified as *A. baumannii* isolates. This study showed the highest resistance of this bacterium towards cefotaxime.

All biofilm producers, including some weak and moderate producers, were found to have the *CsuE* and *OmpA* genes.

Source of Funding: None

Conflict of Interest: None

References

- Gordon NC, Wareham DW. Multidrug-resistant *Acinetobacter baumannii*: mechanisms of virulence and resistance. *Int J Antimicrob Agents*. 2010;35(3):21926. [PubMed] [Google Scholar]
- Ansari H, Doosti A, Kargar M, Bijanzadeh M, Jaafarinia M. Cloning of *ompA* gene from *Acinetobacter baumannii* into the eukaryotic expression vector pBudCE4.1 as DNA vaccine. *Indian J Microbiol*. 2018;58(2):174-81. [PubMed] [Google Scholar]
- Bergogne-Berezin E, Towner KJ. *Acinetobacter* spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. *Clin Microbiol Rev*. 1996;9(2):148-65. [PubMed] [Google Scholar]
- Ansari H, Doosti A, Kargar M, Bizhanzadeh M, Jafarinya M. Cloning and sequencing of the *ompA* and *smpA* virulence genes of *Acinetobacter baumannii* isolated in clinical samples. *Armaghane Danesh*. 2017;21(12):1207-17. [Google Scholar]
- Snitkin ES, Zelazny AM, Montero CI, Stock F, Mijares L; NISC Comparative Sequence Program; Murray PR, Segre JA. Genome-wide recombination drives diversification of epidemic strains of *Acinetobacter baumannii*. *Proc Natl Acad Sci U S A*. 2011;108(33):13758-63. [PubMed] [Google Scholar]
- Wang T, Costa V, Jenkins SG, Hartman BJ, Westblade LF. *Acinetobacter radioresistens* infection with bacteremia and pneumonia. *IDCases*. 2019;15:e00495. [PubMed] [Google Scholar]
- Abdelaal AM, Mahmood SS. The role of efflux Pump *adeJ* gene in levofloxacin resistance among *A. baumannii*. *Syst Rev Pharm*. 2020;11(10):1105-10. [Google Scholar]
- Eze EC, Chenia HY, El Zowalaty ME. *Acinetobacter baumannii* biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. *Infect Drug Resist*. 2018 Nov 15;11:2277-99. [PubMed] [Google Scholar]
- Greene C, Wu J, Rickard AH, Xi C. Evaluation of the ability of *Acinetobacter baumannii* to form biofilms on six different biomedical relevant surfaces. *Lett Appl Microbiol*. 2016;63(4):233-9. [PubMed] [Google Scholar]
- Hall CW, Mah TF. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. *FEMS Microbiol Rev*. 2017;41(3):276-301. [PubMed] [Google Scholar]
- Zeighami H, Valadkhani F, Shapouri R, Samadi E, Haghi F. Virulence characteristics of multidrug resistant biofilm forming *Acinetobacter baumannii* isolated from intensive care unit patients. *BMC Infect Dis*. 2019;19(1):629. [PubMed] [Google Scholar]
- Colquhoun JM, Rather PN. Insights into mechanisms of biofilm formation in *Acinetobacter baumannii* and implications for uropathogenesis. *Front Cell Infect Microbiol*. 2020;10:253. [PubMed] [Google Scholar]
- Bergey DH, Holt JG. *Bergey's manual of determinative bacteriology*. 9th ed. Baltimore: Lippincott Williams and Wilkins; 1994. [Google Scholar]
- Macfaddin JF. *Biochemical tests for identification of medical bacteria*. Baltimore: Lippincott Williams & Williams; 2000.
- CLSI. Performance standards for antimicrobial susceptibility testing. 32nd ed. CLSI document M100-ED32. Wayne, PA: Clinical and Laboratory Standards Institute; 2022.
- Falah F, Shokoohzadeh L, Adabi M. Molecular identification and genotyping of *Acinetobacter baumannii* isolated from burn patients by PCR and ERIC-PCR. *Scars Burn Heal*. 2019 Feb;5:2059513119831369. [PubMed] [Google Scholar]
- Birgani MT, Bijanzadeh M, Ansari H. Antibiotic characterization of *Acinetobacter baumannii* isolated from clinical samples and production of recombinant *OmpA* from resistant strains. *Jundishapur J Microbiol*. 2018;11(12):e78773. [Google Scholar]
- Musyoki VM, Masika MM, Mutai W, Wilfred G, Kuria A, Muthini F. Antimicrobial susceptibility pattern of *Acinetobacter* isolates from patients in Kenyatta National Hospital, Nairobi, Kenya. *Pan Afr Med J*. 2019;33(1):146. [PubMed] [Google Scholar]
- Khatun MN, Farzana R, Lopes BS, Shamsuzzaman SM. Molecular characterization and resistance profile of nosocomial *Acinetobacter baumannii* in intensive care unit of tertiary care hospital in Bangladesh. *Bangladesh Med Res Counc Bull*. 2015;41(2):101-7. [PubMed] [Google Scholar]
- Yang CH, Su PW, Moi SH, Chuang LY. Biofilm formation in *Acinetobacter baumannii*: genotype-phenotype correlation. *Molecules*. 2019;24(10):1849. [PubMed] [Google Scholar]
- Anane YA, Apalata T, Vasaikar S, Okuthe GE, Songca S. Molecular detection of carbapenemase-encoding genes in multidrug-resistant *Acinetobacter baumannii* clinical isolates in South Africa. *Int J Microbiol*. 2020;2020:7380740. [PubMed] [Google Scholar]
- Tarafdar F, Jafari B, Azimi T. Evaluating the antimicrobial resistance patterns and molecular frequency of *bla_{oxa-48}* and *bla_{GES-2}* genes in *Pseudomonas aeruginosa* and *Acinetobacter baumannii* strains isolated from burn wound infection in Tehran, Iran. *New Microbes New Infect*. 2020;37:100686. [PubMed] [Google Scholar]

23. El-Badawy MF, Abdelwahab SF, Alghamdi SA, Shohayeb MM. Characterization of phenotypic and genotypic traits of carbapenem-resistant *Acinetobacter baumannii* clinical isolates recovered from a tertiary care hospital in Taif, Saudi Arabia. *Infect Drug Resist.* 2019;12:3113-24. [PubMed] [Google Scholar]
24. Thummeepak R, Kongthai P, Leungtongkam U, Sitthisak S. Distribution of virulence genes involved in biofilm formation in multi-drug resistant *Acinetobacter baumannii* clinical isolates. *Int Microbiol.* 2016;19(2):121-9. [PubMed] [Google Scholar]
25. Dafopoulou K, Tsakris A, Pournaras S. Changes in antimicrobial resistance of clinical isolates of *Acinetobacter baumannii* group isolated in Greece, 2010–2015. *J Med Microbiol.* 2018;67(4):496-8. [PubMed] [Google Scholar]
26. Abdallah EM, Ahamed F, Al-Omari AS. Antibiotic susceptibility patterns of some clinical isolates from Al-Rass General Hospital. *Int J Biosci.* 2015;6(9):47-54. [Google Scholar]
27. Maraki S, Mantadakis E, Mavromanolaki VE, Kofteridis DP, Samonis G. A 5-year surveillance study on antimicrobial resistance of *Acinetobacter baumannii* clinical isolates from a tertiary Greek hospital. *Infect Chemother.* 2016;48(3):190-8. [PubMed] [Google Scholar]
28. Ranjbar R, Farahani A. Study of genetic diversity, biofilm formation, and detection of Carbapenemase, MBL, ESBL, and tetracycline resistance genes in multidrug-resistant *Acinetobacter baumannii* isolated from burn wound infections in Iran. *Antimicrob Resist Infect Control.* 2019;8:172. [PubMed] [Google Scholar]
29. Lukovic B, Gajic I, Dimkic I, Kekic D, Zornic S, Pozder T, Radisavljevic S, Opavski N, Kojic M, Ranin L. The first nationwide multicenter study of *Acinetobacter baumannii* recovered in Serbia: emergence of OXA-72, OXA-23 and NDM-1-producing isolates. *Antimicrob Resist Infect Control.* 2020;9(1):101. [PubMed] [Google Scholar]
30. Safari M, Saidijam M, Bahador A, Jafari R, Alikhani MY. High prevalence of multidrug resistance and metallo-beta-lactamase (MbetaL) producing *Acinetobacter baumannii* isolated from patients in ICU wards, Hamadan, Iran. *J Res Health Sci.* 2013;13(2):162-7. [PubMed] [Google Scholar]
31. Abd El-Baky RM, Farhan SM, Ibrahim RA, Mahran KM, Hetta HF. Antimicrobial resistance pattern and molecular epidemiology of ESBL and MBL producing *Acinetobacter baumannii* isolated from hospitals in Minia, Egypt. *Alexandria Med J.* 2020;56(1):4-13. [Google Scholar]
32. Abbas-Al-Khafaji ZK, Aubais-aljelehawy QH. Evaluation of antibiotic resistance and prevalence of multi-antibiotic resistant genes among *Acinetobacter baumannii* strains isolated from patients admitted to Al-Yarmouk Hospital. *Cell Mol Biomed Rep.* 2021;1(2):60-8. [Google Scholar]
33. Monfared AM, Rezaei A, Poursina F, Faghri J. Detection of genes involved in biofilm formation in MDR and XDR *Acinetobacter baumannii* isolated from human clinical specimens in Isfahan, Iran. *Arch Clin Infect Dis.* 2019;14(2):e85766. [Google Scholar]
34. Mohammed MA, Ahmed MT, Anwer BE, Aboshanab KM, Aboulwafa MM. Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-*Acinetobacter baumannii* to fluoroquinolones. *PLoS One.* 2020;15(8):e0238195. [PubMed] [Google Scholar]
35. As SG, Priyadarshini JV. CLSI based antibiogram profile and the detection of MDR and XDR strains of *Acinetobacter baumannii* isolated from urine samples. *Med J Islam Repub Iran.* 2019;33:3. [PubMed] [Google Scholar]
36. Salimizand H, Zomorodi AR, Mansury D, Khakshoor M, Azizi O, Khodaparast S, Baseri Z, Karami P, Zamanlou S, Farsiani H, Amini Y, Moradi B, Meshkat Z, Salimizand H, Hasanzadeh S, Sadeghian H. Diversity of aminoglycoside modifying enzymes and 16S rRNA methylases in *Acinetobacter baumannii* and *Acinetobacter nosocomialis* species in Iran; wide distribution of aadA1 and armA. *Infect Genet Evol.* 2018;66:195-9. [PubMed] [Google Scholar]
37. Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. *Acinetobacter baumannii* antibiotic resistance mechanisms. *Pathogens.* 2021;10(3):373. [PubMed] [Google Scholar]
38. Wang YC, Huang TW, Yang YS, Kuo SC, Chen CT, Liu CP, Liu YM, Chen TL, Chang FY, Wu SH, How CK, Lee YT. Biofilm formation is not associated with worse outcome in *Acinetobacter baumannii* bacteraemic pneumonia. *Sci Rep.* 2018;8(1):7289. [PubMed] [Google Scholar]
39. Khoshnood S, Savari M, Montazeri EA, Sheikh AF. Survey on genetic diversity, biofilm formation, and detection of colistin resistance genes in clinical isolates of *Acinetobacter baumannii*. *Infect Drug Resist.* 2020;13:1547-58. [PubMed] [Google Scholar]
40. Ghasemi E, Ghalavand Z, Goudarzi H, Yeganeh F, Hashemi A, Dabiri H, Mirsamadi ES, Foroumand M. Phenotypic and genotypic investigation of biofilm formation in clinical and environmental isolates of *Acinetobacter baumannii*. *Arch Clin Infect Dis.* 2018;13(4):e12914. [Google Scholar]
41. Mohsin MR, AL-Rubaii BA. Bacterial growth and antibiotic sensitivity of *Proteus mirabilis* treated with anti-inflammatory and painkiller drugs. *Biomedicine.* 2023;43(2):728-34. [Google Scholar]

42. Jalil IS, Mohammad SQ, Mohsen AK, Al-Rubaii BA. Inhibitory activity of *Mentha spicata* oils on biofilms of *Proteus mirabilis* isolated from burns. *Biomedicine*. 2023;43(2):748-52. [Google Scholar]
43. Saleh TH, Hashim ST, Malik SN, Al-Rubaii BA. The impact some of nutrients on swarming phenomenon and detection the responsible gene RsbA in clinical isolates of *Proteus mirabilis*. *Int J Res Pharm Sci*. 2020;11(1):437-44.
44. Husain AG, Alrubaii BA. Molecular detection and expression of virulence factor encoding genes of *Pseudomonas aeruginosa* isolated from clinical samples. *Biomedicine*. 2023;43(5):1514-9. [Google Scholar]
45. Al-Saadi HK, Awad HA, Saltan ZS, Hasoon BA, Abdulwahab AI, Al-Azawi KF, Al-Rubaii BA. Antioxidant and antibacterial activities of *Allium sativum* ethanol extract and silver nanoparticles. *Trop J Nat Prod Res*. 2023;7(6):3105-10. [Google Scholar]
46. Abbas MS, Ahmed AG, Ali SQ, AL-Rubaii BA. Immunological inflammatory factors in patients diagnosed with COVID-19. *Biomedicine*. 2023;43(1):230-5. [Google Scholar]
47. Al-Humairi RM, Muhsin HY, Ad'hiah AH. Severity of Coronavirus Disease 19: a profile of inflammatory markers in Iraqi patients. *Malays J Med Health Sci*. 2022;18(1).91-8. [Google Scholar]
48. Hassoon AH. Evaluating the role of mitochondrial DNA quantification in blastocyst transfers potential. *AIP Conf Proc*. 2022;2386(1):020046. [Google Scholar]
49. Buniya HK, Hassoon AH, Hameed AK. Molecular genetic variability in the d-loop region for females with breast cancer and the effect of the chemotherapy. *Res J Pharm Technol*. 2018;11(9):3787-92. [Google Scholar]
50. Rasoul LM, Marhoon AA, Albaayit SF, Ali RW, Saleh TH, Al-Rubaii BA. Cytotoxic effect of cloned EGFP gene on NCI-H727 cell line via genetically engineered gene transfer system. *Biomedicine*. 2022;42(5):938-42. [Google Scholar]
51. Bresam S, Al-Jumaily RM, Karim GF, Al-Rubaii BA. Polymorphism in SNP rs972283 of the KLF14 gene and genetic disposition to peptic ulcer. *Biomedicine*. 2023;43(1):216-20. [Google Scholar]
52. Ismael MK, Qaddoori YB, Shaban MN, Laftaah AR. The immunohistochemical staining of vimentin and e-cadherin in bladder cancer patients infected with hepatitis C virus. *J Pure Appl Microbiol*. 2023;17(2):1009-16. [Google Scholar]
53. Bresam S, Alhumairi RM, Hade IM, Al-Rubaii BA. Genetic mutation rs972283 of the KLF14 gene and the incidence of gastric cancer. *Biomedicine (India)*. 2023;43(4):1256-60. [Google Scholar]
54. Hamoode RH, Alkubaisy SA, Sattar DA, Hamzah SS, Saleh TH, Al-Rubaii BA. Detection of anti-testicular antibodies among infertile males using indirect immunofluorescent technique. *Biomedicine*. 2022;42(5):978-82. [Google Scholar]
55. Rasoul LM, Allami RH, Alshibib AL, Al-Rubaii BA, Sale TH. Expression and cytotoxic effect of recombinant Newcastle Disease Virus (rNDV) vector expressing enhanced green fluorescent gene in JHH5 cell line. *Biomedicine*. 2023;43(1):205-9. [Google Scholar]
56. Jawad NK, Numan AT, Ahmed AG, Saleh TH, Al-Rubaii BA. IL-38 gene expression: a new player in Graves' ophthalmopathy patients in Iraq. *Biomedicine*. 2023;43(1):210-5. [Google Scholar]
57. Al-Humairi RM, Al-Musawi MT, Ad'hiah AH. Bidirectional expression of Toll-like receptor 7 gene in urinary bladder cancer and urinary tract infection of Iraqi patients. *Gene Rep*. 2019;17:100491. [Google Scholar]